Manic episode
Methodology & AI Transparency ⓘ
Manic episode Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Cataloged under federal diagnostic code F30.9 in Depression & Mood, Manic episode requires medical mimic exclusion in Manic episode (F30.9: (thyroid) so specialists can calibrate treatment intensity against Serum Vitamin D in Manic episode (F30.9: & RBC Folate) benchmarks.
- 2 Real-world patient consensus: Diagnostic registry F30.9: Manic episode is managed within Depression & Mood.
- 3 Typical cash cost range: Clinicians assessing Manic episode focus on neuroinflammatory microglial priming [Manic episode F30.9] and targeted history.
- 4 Top reported side effects / signs: Follow-up benchmark in Manic episode: maintaining Serum Vitamin D in Manic episode (F30.9: & RBC Folate) within 25(OH)D 40 – 65 ng/mL (F30.9).
Ask our AI Specialists anything about Manic episode
What Is Manic episode?
Cataloged under federal diagnostic code F30.9 in Depression & Mood, Manic episode requires medical mimic exclusion in Manic episode (F30.9: (thyroid) so specialists can calibrate treatment intensity against Serum Vitamin D in Manic episode (F30.9: & RBC Folate) benchmarks.
Pathophysiology, Underlying Causes & Clinical Presentation
Tissue-level etiology in Manic episode (F30.9) features neuroinflammatory microglial priming [Manic episode F30.9]. therapeutic stabilization in depression & mood is verified against PHQ-9 Symptom Severity in Manic episode (F30.9: Score).
Common Symptoms & Clinical Signs
- • Presentation of Manic episode (F30.9): persistent low mood, in Manic episode (F30.9: emotional flatness, or)
- • Secondary Manic episode clinical sign: disrupted sleep architecture [Manic episode F30.9]
- • Symptom flares in Manic episode correlating with Serum Vitamin D in Manic episode (F30.9: & RBC Folate) deviation outside 25(OH)D 40 – 65 ng/mL (F30.9)
- • Functional depression & mood impact requiring medical mimic exclusion in Manic episode (F30.9: (thyroid) evaluation (F30.9)
Manic episode Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | F30.9 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Depression, Bipolar & Mood Disorders | NLM Clinical Tables |
| Diagnostic / Lab Marker: Serum Vitamin D in Manic episode (F30.9: & RBC Folate) | 25(OH)D 40 – 65 ng/mL (F30.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: PHQ-9 Symptom Severity in Manic episode (F30.9: Score) | < 4 (clinical remission) (F30.9) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: TSH & Free in Manic episode (F30.9: T4 Rule-Out) | TSH 0.8 – 2.5 mIU/L (F30.9) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Manic episode
Treatment selection for Manic episode depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Manic episode)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sertraline treatment of major depression in patients with acute MI or unstable: What a 369-Participant Study Found Our results suggest that sertraline is a safe and effective treatment for recurrent depression in patients with recent MI or unstable angina and without other life-threatening medical conditions. JAMA • 2002-08-14 • Randomized Controlled Trial | N = 369 | 93/100 | PMID 12169073 ↗ |
| Can This Approach Help? Inside the Latest Research on Impact of missing data on clinical trials: a re-analysis of a placebo controlled There is no difference between hypericum and placebo, regardless of the assumption about the missing data process. Psychopharmacology • 2014-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 24232445 ↗ |
| Can This Approach Help? Inside the Latest Research on Efficacy of Add-on Pregabalin in the Treatment of Patients with Generalized There was no significant difference in any of the primary or secondary outcomes or response and full symptom relief rates concerning any analysis (last observation carried-forward of at least visit 2 or completers) between the... Pharmacopsychiatry • 2019-07-15 • Randomized Controlled Trial | N = 31 | 88/100 | PMID 30170329 ↗ |
| Can This Approach Help? Inside the Latest Research on Antipsychotic medication on functional connectivity in depression with psychotic There were no differences in changes in network topology measures when patients stayed on olanzapine or switched to placebo. Molecular psychiatry • 2023-08-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 37258617 ↗ |
| Can This Approach Help? Inside the Latest Research on Cariprazine on reducing symptoms of irritability, hostility, and agitation in Cariprazine demonstrated specific antihostility/irritability and anti-agitation effects in patients with manic/mixed episodes of bipolar I disorder and baseline hostility, irritability, or agitation. Journal of affective disorders • 2024-08-01 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 38657773 ↗ |
Manic episode Patient Community & “People Like Me” Threads
Filter Manic episode community threads and patient logs by age, biological sex, dosage, and treatment duration.